Resultats de la cerca - David Grayzel

  • Mostrar 1 - 6 resultats de 6
Refinar resultats
  1. 1
    Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells

    Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells per Cong Peng, Julia Brain, Yiguo Hu, Ami Goodrich, Linghong Kong, David Grayzel, Roger H. Pak, Margaret Read, Shaoguang Li

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model

    Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model per Steve Vermeersch, Robert J. Benschop, Anne Van Hecken, David Monteith, Victor J. Wroblewski, David Grayzel, Jan de Hoon, Emily C. Collins

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers per David Monteith, Emily C. Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad, Joel C. Scherer, David Grayzel, Thomas Schuetz, Jan de Hoon

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

    A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas per Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael A. Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

    Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer per Lecia V. Sequist, Scott Gettinger, Neil Senzer, Renato Martins, Pasi A. Jänne, Rogerio Lilenbaum, Jhanelle E. Gray, A. John Iafrate, Ryohei Katayama, Nafeeza Hafeez, Jennifer Sweeney, John R. Walker, Christian Fritz, Robert W. Ross, David Grayzel, Jeffrey A. Engelman, Darrell R. Borger, Guillermo Paez, Ronald B. Natale

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

    Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 per Jens Sydor, Emmanuel Normant, Christine Pien, James R. Porter, Jie Ge, Louis Grenier, Roger H. Pak, Janid A. Ali, Marlene S. Dembski, Jebecka Hudak, Jon S. Patterson, Courtney Penders, Melissa Pink, Margaret Read, Jim Sang, Caroline Woodward, Yilong Zhang, David Grayzel, James R. Wright, John Barrett, Vito J. Palombella, Julian Adams, Jeffrey K. Tong

    Publicat 2006
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: